The partnership forged by Novo Nordisk (NVO) and Hims & Hers (HIMS) in April appeared to bring together two giant brands in ...

Hims & Hers Health, Inc. (HIMS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea ...

Granted, defense is not a new theme. The Global X Defense Tech ETF SHLD, which has hot plays including Palantir Technologies (PLTR) and Germany's Rheinmetall (XE:RHM), has surged 54% this year. The ...

Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...

Hims & Hers fell by 34.63 percent on Monday to close at $41.98 apiece after Novo Nordisk terminated its marketing partnership ...

Novo Nordisk shares tumble 5.6% after ending Hims & Hers partnership and releasing disappointing CagriSema obesity drug trial ...

U.S. stocks went up and oil prices fell this week as investors hoped that Iran would not block the global supply of oil, even ...

The Novo Nordisk partnership ending does not alter my long-term bullish thesis on HIMS; the company is much more than just a ...

Novo Nordisk (NYSE: NVO) and Hims & Hers Health (NYSE: HIMS) announced they were collaborating to allow Hims & Hers to sell ...

Hims & Hers Health, a telehealth company, offers direct-to-patient platform to distribute prescription drugs and OTC ...

As voters head to the polls, the democratic socialist candidate appears to be neck-and-neck with Andrew Cuomo. That has many ...

Novo Nordisk ends Wegovy deal with Hims over legal issues, sending the stock tumbling. What happens next? Here's a look.